Evidence map›Paper›PMID 34268378›Full record

ArticleAnnals of translational medicine2021

Construction and validation of a prognostic signature using CNV-driven genes for hepatocellular carcinoma.

Jin Bian, Junyu Long, Xu Yang, Xiaobo Yang, Yiyao Xu, Xin Lu, Mei Guan, Xinting Sang, Haitao Zhao

Open access · diamondAbstract read
In one paragraph

Article in Annals of translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Jin BianDepartment of Liver Surgery, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC), Beijing, China.
Junyu LongDepartment of Liver Surgery, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC), Beijing, China.
Xu YangDepartment of Liver Surgery, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC), Beijing, China.
Xiaobo YangDepartment of Liver Surgery, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC), Beijing, China.
Yiyao XuDepartment of Liver Surgery, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC), Beijing, China.
Xin LuDepartment of Liver Surgery, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC), Beijing, China.
Mei GuanDepartment of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC), Beijing, China.
Xinting SangDepartment of Liver Surgery, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC), Beijing, China.
Haitao ZhaoDepartment of Liver Surgery, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC), Beijing, China.
Peking Union Medical College Hospital · CNChinese Academy of Medical Sciences & Peking Union Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatocellular carcinoma (HCC) is one of the major causes of cancer-related deaths worldwide. Copy number variations (CNVs) affect the expression of genes and play critical roles in carcinogenesis. We aimed to identify specific CNV-driven genes and establish a prognostic model for HCC.

methodsIntegrative analysis of CNVs difference data and differentially expressed genes (DEGs) data from The Cancer Genome Atlas (TCGA) were conducted to identify critical CNV-driven genes for HCC. A risk model was constructed based on univariate Cox regression analysis, Least Absolute Shrinkage and Selection Operator (LASSO), and multivariate Cox regression analyses. The associations between CNV-driven genes signature and infiltrating immune cells were explored. The International Cancer Genome Consortium (ICGC) dataset was utilized to validate this model.

resultsAfter integrative analysis of CNVs and corresponding mRNA expression profiles, 568 CNV-driven genes were identified. Sixty-three CNV-driven genes were found to be markedly associated with overall survival (OS) after univariate Cox regression analysis. Finally, eight CNV-driven genes were screened to generate a prognostic risk model. Compared with low-risk group, the OS of patients in the high-risk group was significantly shorter in both the TCGA [hazard ratio (HR) =6.14, 95% confidence interval (CI): 2.72-13.86, P<0.001] and ICGC (HR =3.23, 95% CI: 1.17-8.92, P<0.001) datasets. Further analysis revealed the infiltrating neutrophils were positively correlated with risk score. Meanwhile, the high-risk group was associated with higher expression of immune checkpoint genes.

conclusionsA novel signature based on CNV-driven genes was built to predict the survival of HCC patients and showed good performance. The results of our study may improve understanding of the mechanism that drives HCC, and provide an immunological perspective for individualized therapies.

Indexed as

Copy number variation-driven genes (CNV-driven genes)hepatocellular carcinoma (HCC)immune microenvironmentprognosis

Identifiers

PMID34268378
PMCPMC8246234
OpenAlexW3157024694

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.